查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1696208

全球多組學市場 - 2025 至 2033 年

Global Multi-omics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球多組學市場規模達到 32.5 億美元，預計到 2033 年將達到 332.5 億美元，2025-2033 年預測期內的複合年成長率為 26.1%。

多組學是一種整合各種組學技術的多學科方法，透過分析來自各個分子層的資料來幫助發現生物標記，了解疾病機制並推進個人化醫療。

由於精準醫療的採用、藥物發現研究和定序技術，全球多組學市場正經歷顯著成長。關鍵促進因素包括對綜合生物資料分析、政府資助以及醫療保健和生物技術應用的需求。北美憑藉著強大的研究基礎設施引領市場，而亞太地區正成為一個利潤豐厚的地區。賽默飛世爾科技、Illumina 和 QIAGEN 等主要參與者正在推動該領域的創新。

市場動態：

促進因素與約束因素

精準醫療的應用日益廣泛

全球多組學市場受到精準醫療日益成長的關注所推動，精準醫療可以讓人們更深入地了解個人基因、蛋白質體學和代謝特徵。政府和醫療保健組織正在大力投資多組學研究，以開發針對癌症和神經系統疾病等複雜疾病的個人化治療方法。人工智慧與生物資訊學的融合加速了藥物發現和針對患者的治療策略。

例如，2025 年 1 月，3D 基因組學技術的先驅 Enhanc3D Genomics 推出了一套整合的多組學解決方案，以提高藥物發現的精確度。該解決方案基於該公司專有的3D基因組學平台，為合作夥伴提供全面的端到端解決方案，以支援整個藥物發現和開發過程的決策。

數據複雜性與整合

全球多組學市場因資料複雜性和整合性而面臨挑戰，因為它從基因組學、轉錄組學、蛋白質組學和代謝組學產生了大量異質資料。這需要先進的計算工具來進行有意義的解釋、跨平台的標準化以及資料庫之間的互通性。確保資料的準確性、可重複性和可擴展性需要高效能運算和複雜的演算法，這限制了小型研究組織和臨床應用的可近性。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品和服務分類的摘要
  • 技術片段
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 精準醫療的應用日益廣泛
      • 定序技術的進步
    • 限制
      • 數據複雜性與整合
      • 監管和道德問題
    • 機會
      • 基於雲端的多組學解決方案的開發
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大、最暢銷品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 5 章：按產品和服務

  • 儀器
  • 耗材和試劑
  • 服務

第 6 章：按技術

  • 基因組學
  • 轉錄組學
  • 蛋白質體學
  • 代謝組學
  • 表觀基因組學

第 7 章：按應用

  • 藥物研發
  • 精準醫療
  • 臨床診斷
  • 生物技術與工業應用

第 8 章：按最終用戶

  • 製藥及生技公司
  • 研究機構和學術中心
  • 醫院和診所
  • CRO 和 CDMO

第9章：區域市場分析與成長機會

  • 北美洲
    • 各區域關鍵動態
      • 美國
      • 加拿大
  • 歐洲
    • 各區域關鍵動態
      • 德國
      • 英國
      • 法國
      • 西班牙
      • 義大利
      • 歐洲其他地區
  • 拉丁美洲
    • 各區域關鍵動態
      • 墨西哥
      • 巴西
      • 阿根廷
      • 拉丁美洲其他地區
  • 亞太
    • 各區域關鍵動態
      • 中國
      • 印度
      • 日本
      • 韓國
      • 亞太其他地區
  • 中東和非洲
    • 各區域關鍵動態

第 10 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第 11 章：公司簡介

  • BD (Becton, Dickinson and Company)
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Thermo Fisher Scientific Inc
  • Illumina, Inc
  • Danaher Corporation
  • Bruker Corporation
  • QIAGEN NV
  • Agilent Technologies, Inc
  • Genedata
  • Shimadzu Corporation
  • Element Biosciences

第 12 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 13 章：附錄

簡介目錄
Product Code: BT7715

The global multi-omics market reached US$ 3.25 Billion in 2024 and is expected to reach US$ 33.25 Billion by 2033, growing at a CAGR of 26.1% during the forecast period 2025-2033.

Multiomics is a multidisciplinary approach that integrates various omics technologies, aiding in the discovery of biomarkers, understanding disease mechanisms, and advancing personalized medicine by analyzing data from various molecular layers.

The global multiomics market is experiencing significant growth due to precision medicine adoption, drug discovery research, and sequencing technologies. Key drivers include demand for integrated biological data analysis, government funding, and healthcare and biotechnology applications. North America leads the market due to strong research infrastructure, while Asia-Pacific is emerging as a lucrative region. Major players like Thermo Fisher Scientific, Illumina, and QIAGEN are driving innovation in this field.

Market Dynamics: Drivers & Restraints

Rising Adoption of Precision Medicine

The global multiomics market is driven by the growing focus on precision medicine, which allows for a deeper understanding of individual genetic, proteomic, and metabolic profiles. Governments and healthcare organizations are investing heavily in multiomics research to develop personalized therapies for complex diseases like cancer and neurological disorders. The integration of artificial intelligence and bioinformatics accelerates drug discovery and patient-specific treatment strategies.

For instance, in January 2025, Enhanc3D Genomics, a pioneer in 3D genomics technology, launched a suite of integrated multi-omics solutions to enhance drug discovery precision. The solutions, based on the company's proprietary 3D genomics platform, provide partners with a comprehensive end-to-end solution to support decision-making throughout the drug discovery and development process.

Data Complexity and Integration

The global multiomics market faces challenges due to data complexity and integration, as it generates vast heterogeneous data from genomics, transcriptomics, proteomics, and metabolomics. This requires advanced computational tools for meaningful interpretation, standardization across platforms, and interoperability between databases. Ensuring data accuracy, reproducibility, and scalability requires high-performance computing and sophisticated algorithms, which limits accessibility for smaller research organizations and clinical applications.

Segment Analysis

The global multi-omics market is segmented based on product & service, technology, application, end-user, and region.

Product & Service:

The instruments from the product & service segment are expected to dominate the multi-omics market with the highest market share.

Multiomics instruments, including NGS platforms, mass spectrometers, and microarrays, are specialized lab equipment used in various omics fields for precise detection, quantification, and characterization of biological molecules, enabling high-throughput data generation and drug development.

Instruments are vital in the global multiomics market, enabling precise analysis of biological molecules in genomics, transcriptomics, proteomics, and metabolomics. Advanced sequencing platforms, mass spectrometers, chromatography systems, and imaging technologies generate high-resolution data, facilitating molecular profiling, biomarker discovery, and disease mechanism studies. Continuous innovations in automation, miniaturization, and high-throughput analysis improve efficiency and accessibility, making multiomics technologies more accessible for research institutes, biotechnology companies, and clinical laboratories.

For instance, in June 2024, Mission Bio launched the Tapestri Single-cell Multiple Myeloma Multiomics Solution, a product suite designed to revolutionize multiple myeloma research and therapeutic development. The suite offers comprehensive insights into disease evolution and biology at the single-cell level, enabling researchers and drug developers to understand therapy resistance and disease relapse at the subclonal level. This new product suite will enhance the understanding of disease progression and treatment resistance.

Geographical Analysis

North America is expected to hold a significant position in the multi-omics market with the highest market share

North America leads the global multi-omics market due to its significant product launches, robust research infrastructure, government funding, and key industry players. The region's biotechnology and pharmaceutical sectors invest in multi-omics technologies for drug discovery, precision medicine, and clinical diagnostics. Advanced sequencing platforms, bioinformatics tools, and AI-driven analytics enhance research capabilities.

For instance, in September 2024, The Translational Genomics Research Institute (TGen), part of the City of Hope, launched the Center for Spatial Multi-Omics (COSMO), a service center aimed at transforming biomedical research through spatial biology. COSMO offers services to visualize and map molecular data at the single-cell level within tissues, preserving important cellular environments and structures for histological analysis. Advanced technologies enable researchers to examine thousands of RNA targets in detail.

Moreover, partnerships and collaborations between academic institutions and biotech firms accelerate innovation which indeed helps the region to grow during the forecast period. For instance, in January 2024, Thermo Fisher Scientific Inc. and Akoya Biosciences signed a license and distribution agreement to provide a comprehensive solution for spatial multi-omics workflows, simplifying the whole-slide, multi-omics imaging process and examining protein and RNA, crucial for cancer research fields.

Furthermore, in January 2024, BD partnered with Hamilton Company to create robotics-compatible and automated reagent kits for large-scale single-cell multi-omics experiments, aiming to standardize and minimize human error.

Competitive Landscape

The major global players in the multi-omics market include BD (Becton, Dickinson, and Company), Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, Bruker Corporation, QIAGEN N.V, Agilent Technologies, Inc., Genedata, Shimadzu Corporation, and Element Biosciences among others.

Key Developments

  • In May 2024, QIAGEN launched its QIAseq Multimodal DNA/RNA Library Kit, which enables the preparation of DNA and RNA libraries for next-generation sequencing, including whole genome sequencing and whole transcriptome sequencing, and downstream target enrichment using hybrid-capture from a single sample.
  • In June 2023, Singleton, a trusted partner for scientists and clinicians, launched two new single-cell multi-omics products: NEO and Python Junior. These portable instruments are designed to fit into any laboratory and deliver accurate and reproducible results. The NEO library processing system and Python Junior tissue dissociation instrument aim to make single-cell sequencing accessible for every laboratory, ensuring accurate and reproducible results for researchers and clinicians alike.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global multi-omics market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product & Service
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Adoption of Precision Medicine
      • 3.1.1.2. Advancements in Sequencing Technologies
    • 3.1.2. Restraints
      • 3.1.2.1. Data Complexity and Integration
      • 3.1.2.2. Regulatory and Ethical Concerns
    • 3.1.3. Opportunity
      • 3.1.3.1. Development of Cloud-Based Multi-omics Solutions
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Product & Service

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 5.1.2. Market Attractiveness Index, By Product & Service
  • 5.2. Instruments*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Consumables & Reagents
  • 5.4. Services

6. By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Genomics*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Transcriptomics
  • 6.4. Proteomics
  • 6.5. Metabolomics
  • 6.6. Epigenomics

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Drug Discovery & Development*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Precision Medicine
  • 7.4. Clinical Diagnostics
  • 7.5. Biotechnology & Industrial Applications

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Pharmaceutical & Biotechnology Companies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Research Institutes & Academic Centers
  • 8.4. Hospitals & Clinics
  • 8.5. CROs & CDMOs

9. Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Mexico
      • 9.4.7.2. Brazil
      • 9.4.7.3. Argentina
      • 9.4.7.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. BD (Becton, Dickinson and Company) *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Thermo Fisher Scientific Inc
  • 11.3. Illumina, Inc
  • 11.4. Danaher Corporation
  • 11.5. Bruker Corporation
  • 11.6. QIAGEN N.V
  • 11.7. Agilent Technologies, Inc
  • 11.8. Genedata
  • 11.9. Shimadzu Corporation
  • 11.10. Element Biosciences

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us